The pulse of Masimo Corporation's (MASI +0.02%) business felt quite strong when the company reported its 2017 fourth-quarter results in February. Masimo's revenue and adjusted earnings soared on solid sales growth for its SET pulse oximeters.
Masimo announced its 2018 first-quarter results after the market closed on Wednesday. This time around, the company had a record quarter, but its growth slowed down somewhat. Here are the highlights from Masimo's update.
Image source: Masimo.
Masimo results: The raw numbers
| Metric |
Q1 2018 |
Q1 2017 |
Year-Over-Year Change |
|---|---|---|---|
|
Sales | $213 million | $196.6 million |
8.3% |
|
Net income from continuing operations | $45.6 million | $51.5 million |
(11.5%) |
|
Adjusted earnings per share (EPS) | $0.75 | $0.65 |
15.4% |
Data source: Masimo.
What happened with Masimo this quarter?
Masimo makes its money in three primary ways: direct product revenue, OEM (original equipment manufacturer) product sales, and royalties and other revenue. The company had good news in two of the three areas.
Direct product revenue, which contributes 87.5% of Masimo's total product revenue, increased to $178.9 million in the first quarter. OEM product sales, which make up the rest of the company's product revenue, grew to $25.5 million. However, first-quarter royalties and other revenue fell to $8.6 million from $14.2 million in the prior-year period.
While Masimo's total revenue increased, the company's GAAP net income fell from the first quarter of 2017. There were two primary causes of this decline. One was a $6.2 million positive adjustment for revenue from contracts with customers posted in the prior-year period that wasn't there in the first quarter of 2018. Without this GAAP adjustment, Masimo's net income would have increased slightly year over year. In addition, Masimo paid more in taxes in the first quarter of 2018 than it did in the prior-year period.
The company's non-GAAP adjusted EPS looked much better, though. This stemmed largely from a bigger hit in the first quarter of 2017 for excess tax benefits from stock-based compensation.
Masimo ended the first quarter with cash and cash equivalents totaling $369.5 million. This cash stockpile would have been even bigger, but the company spent $16.5 million buying back stock.
What management had to say
Masimo chairman and CEO Joe Kiani stated:
We had another record quarter for product revenues and earnings, demonstrating once again the clinical and economic value of our innovative technologies for improving patient care. We achieved another strong quarter of shipments of our noninvasive monitoring technologies, at 53,600. Our positive outlook is visible in our higher guidance for sales and earnings in 2018 as we introduce important new products and gain new customers around the world.
Looking forward
The strong performance in the first quarter prompted Masimo to boost its full-year 2018 guidance. The company now expects total revenue of $846 million, up from the previous guidance of $836 million. Masimo expects GAAP diluted EPS of $3.01 and adjusted non-GAAP diluted EPS of $2.88. Its previous outlook called for GAAP EPS of $2.90 and non-GAAP EPS of $2.80.
Several new products introduced in recent months could contribute to Masimo's growth later this year. The company is now marketing its Eve critical congenital heart disease (CCHD) newborn screening application for the Rad-9 Pulse CO-Oximeter in Europe. In April, Masimo launched the UniView integrated display of real-time data and alarms from multiple Masimo and third-party devices. Also, the company can now sell its Rad-97 Pulse CO-Oximeter with integrated NomoLine capnography in Europe. The device was already available in the U.S.
